[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100055343":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":7,"centralContacts":7,"locations":14,"responsibleParty":7,"collaborators":7,"id":101,"slug":102,"hasResults":103,"nctId":104,"briefTitle":105,"officialTitle":106,"acronym":7,"eligibilityCriteria":107,"healthyVolunteers":103,"sex":108,"minAge":109,"maxAge":110,"enrollmentInfo":111,"targetDuration":7,"studyType":113,"phases":114,"briefSummary":116,"conditions":117,"keywords":120,"overallStatus":127,"whyStopped":7,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":7,"completionDateStruct":7,"leadSponsor":132,"locationsCount":134},{"fullName":5,"class":6},"NIH AIDS Clinical Trials Information Service","INDUSTRY",null,[9,12],{"type":10,"name":11,"description":7,"armGroupLabels":7,"otherNames":7},"DRUG","Cidofovir",{"type":10,"name":13,"description":7,"armGroupLabels":7,"otherNames":7},"Probenecid",[15,28,37,46,56,66,76,86,96],{"facility":16,"status":7,"city":17,"state":18,"zip":19,"country":20,"countryCode":21,"cosmosGeoPoint":22,"geoPoint":27,"contacts":7},"Los Angeles County - USC Med Ctr","Los Angeles","California","90033","United States","US",{"type":23,"coordinates":24},"Point",[25,26],-118.24368,34.05223,{"lat":26,"lon":25},{"facility":29,"status":7,"city":30,"state":18,"zip":31,"country":20,"countryCode":21,"cosmosGeoPoint":32,"geoPoint":36,"contacts":7},"UCI Med Ctr","Orange","92668",{"type":23,"coordinates":33},[34,35],-117.85311,33.78779,{"lat":35,"lon":34},{"facility":38,"status":7,"city":39,"state":18,"zip":40,"country":20,"countryCode":21,"cosmosGeoPoint":41,"geoPoint":45,"contacts":7},"Mount Zion Med Ctr","San Francisco","94115",{"type":23,"coordinates":42},[43,44],-122.41942,37.77493,{"lat":44,"lon":43},{"facility":47,"status":7,"city":48,"state":49,"zip":50,"country":20,"countryCode":21,"cosmosGeoPoint":51,"geoPoint":55,"contacts":7},"Beth Israel Hosp","Boston","Massachusetts","02215",{"type":23,"coordinates":52},[53,54],-71.05977,42.35843,{"lat":54,"lon":53},{"facility":57,"status":7,"city":58,"state":59,"zip":60,"country":20,"countryCode":21,"cosmosGeoPoint":61,"geoPoint":65,"contacts":7},"Besselaar Associates","Princeton","New Jersey","085406681",{"type":23,"coordinates":62},[63,64],-74.65905,40.34872,{"lat":64,"lon":63},{"facility":67,"status":7,"city":68,"state":69,"zip":70,"country":20,"countryCode":21,"cosmosGeoPoint":71,"geoPoint":75,"contacts":7},"Univ of Rochester Med Ctr","Rochester","New York","14607",{"type":23,"coordinates":72},[73,74],-77.61556,43.15478,{"lat":74,"lon":73},{"facility":77,"status":7,"city":78,"state":79,"zip":80,"country":20,"countryCode":21,"cosmosGeoPoint":81,"geoPoint":85,"contacts":7},"Univ of North Carolina Hosps","Chapel Hill","North Carolina","27599",{"type":23,"coordinates":82},[83,84],-79.05584,35.9132,{"lat":84,"lon":83},{"facility":87,"status":7,"city":88,"state":89,"zip":90,"country":20,"countryCode":21,"cosmosGeoPoint":91,"geoPoint":95,"contacts":7},"Audie L Murphy Veterans Administration Hosp","San Antonio","Texas","78284",{"type":23,"coordinates":92},[93,94],-98.49363,29.42412,{"lat":94,"lon":93},{"facility":97,"status":7,"city":98,"state":7,"zip":7,"country":99,"countryCode":100,"cosmosGeoPoint":7,"geoPoint":7,"contacts":7},"Charing Cross and Westminster Med School","London Southwest 10","United Kingdom","UK","100055343","phase-2-the-safety-and-effectiveness-of-cidofovir-in-the-treatment-of-cytomegalovirus-cmv-of-the-eyes-in-patients-with-aids-100055343",false,"NCT00002437","The Safety and Effectiveness of Cidofovir in the Treatment of Cytomegalovirus (CMV) of the Eyes in Patients With AIDS","A Phase II\u002FIII Study of the Safety and Efficacy of 1-(S)-(3-Hydroxy-2-Phosphonylmethoxypropyl)Cytosine Dihydrate (Cidofovir; HPMPC) for the Treatment of Peripheral Cytomegalovirus Retinitis in Patients With AIDS","Inclusion Criteria\n\nConcurrent Medication:\n\nAllowed:\n\n* Antiretroviral agents.\n* Oral trimethoprim\u002Fsulfamethoxazole.\n* Aerosolized pentamidine.\n* Dapsone.\n* Fluconazole.\n* Rifabutin.\n* Filgrastim (G-CSF).\n* p24 vaccine.\n\nPatients must have:\n\n* Diagnosis of AIDS by CDC criteria.\n* Diagnosis of peripheral (not immediately sight-threatening) CMV retinitis.\n* Visual acuity in the affected eye of \\>= three lines on the ETDRS (Early Treatment Diabetic Retinopathy Study) chart at 1 m distance.\n* Life expectancy of at least 3 months.\n* Consent of parent or guardian in patients less than 18 years of age.\n\nPrior Medication:\n\nAllowed:\n\n* Acyclovir.\n* Prior ganciclovir, foscarnet, or CMV hyperimmune immunoglobulin if given solely as prophylaxis.\n\nExclusion Criteria\n\nCo-existing Condition:\n\nPatients with the following symptoms or conditions are excluded:\n\n* Media opacity that precludes visualization of the fundus of both eyes.\n* Retinal detachment.\n* Clinically significant cardiac disease, including symptoms of ischemia, congestive heart failure, or arrhythmia.\n* Active medical problems considered sufficient to hinder study compliance.\n* Known clinically significant allergy to probenecid.\n\nConcurrent Medication:\n\nExcluded:\n\n* Acyclovir (may be reinstituted following development of herpetic lesions).\n* Ganciclovir.\n* Foscarnet.\n* Amphotericin B.\n* Diuretics.\n* Aminoglycoside antibiotics.\n* CMV hyperimmune immunoglobulin.\n* Intravenous pentamidine.\n* Other nephrotoxic agents.\n* Other investigational drugs with potential nephrotoxicity.\n\nPrior Medication:\n\nExcluded:\n\n* Prior ganciclovir, foscarnet, or CMV hyperimmune immunoglobulin as therapy for CMV disease (although permitted if previously received solely as prophylaxis).\n\nExcluded within 1 week prior to study entry:\n\n* Amphotericin B.\n* Vidarabine.\n* Other nephrotoxic agents.\n* Aminoglycoside antibiotics.\n* Intravenous pentamidine. Drug or alcohol abuse.","ALL","13 Years","60 Years",{"count":112,"type":7},48,"INTERVENTIONAL",[115],"PHASE2","To determine whether cidofovir (HPMPC) therapy administered by intravenous infusion can extend the time to progression of peripheral cytomegalovirus (CMV) retinitis in AIDS patients. To evaluate the safety and tolerance of HPMPC therapy when administered by intravenous infusion in AIDS patients with CMV retinitis that is not immediately sight-threatening. To evaluate the virologic effects of intravenous HPMPC therapy on CMV shedding in urine, blood, and\u002For semen. To evaluate the impact of HPMPC therapy on visual acuity.",[118,119],"Cytomegalovirus Retinitis","HIV Infections",[121,13,122,123,124,125,126],"Retinitis","Drug Therapy, Combination","Cytomegalovirus Infections","Acquired Immunodeficiency Syndrome","Antiviral Agents","cidofovir","COMPLETED","2005-06-23",{"date":130,"type":131},"2005-06-24","ESTIMATED",{"name":133,"class":6},"Gilead Sciences",9]